Alcista
$284.42
Precio del escenario
$238.970
-3.226 (-1.35%)Al cierre
ResMed Inc. is a holding company. The Company, through its subsidiaries, in the development, manufacturing, distribution and marketing of medical devices and cloud-based software applications that diagnose, treat and manage respiratory disorders, including sleep disordered breathing (SDB), chronic obstructive pulmonary disease, neuromuscular disease and other chronic diseases. Its segments include Sleep and Breathing Health segment and the Residential Care Software segment. It also operates a Software as a Service (SaaS) business in the United States and Germany that includes out-of-hospital software platforms designed to support the professionals and caregivers who help people stay healthy in the home or care setting of their choice. Its products and solutions are designed to improve patients' quality of life and reduce the impact of chronic disease. Its cloud-based digital health software applications, along with its devices, are designed to provide connected care.
ResMed Inc. is a good buy right now due to its current price of $238.97 being below the analyst price targets of $262 and $267, indicating significant upside potential. The stock has shown a strong RSI of 72.818, suggesting bullish momentum, and a solid gross margin of 58.12%, indicating good profitability. However, the recent insider selling by the CEO, who sold nearly 5,000 shares, may raise concerns about future performance, which is a risk to consider.
RBC Capital
$262
2026-09-15
RBC Capital
2026-09-15
Precio objetivo
$262
Citi
$240
2026-09-10
Citi
2026-09-10
Precio objetivo
$240
KeyBanc
$267
2026-08-31
KeyBanc
2026-08-31
Precio objetivo
$267
Rothschild & Co Redburn
$230
2026-08-19
Rothschild & Co Redburn
2026-08-19
Precio objetivo
$230
RBC Capital
$244
2026-08-07
RBC Capital
2026-08-07
Precio objetivo
$244
Los precios por escenario son la última banda de previsión mensual del año en curso. Las probabilidades son pesos fijos del modelo (25 / 50 / 25), no garantías.

Latest Rating Updates from Wall Street

Resmed CEO Sells Nearly 5,000 Shares

ResMed Partners with 23XI Racing to Raise Sleep Health Awareness

Resmed Partners with 23XI Racing to Promote Sleep Health Awareness

ResMed Appoints New Lead Director
ResMed Inc. is a holding company. The Company, through its subsidiaries, in the development, manufacturing, distribution and marketing of medical devices and cloud-based software applications that diagnose, treat and manage respiratory disorders, including sleep disordered breathing (SDB), chronic obstructive pulmonary disease, neuromuscular disease and other chronic diseases. Its segments include Sleep and Breathing Health segment and the Residential Care Software segment. It also operates a Software as a Service (SaaS) business in the United States and Germany that includes out-of-hospital software platforms designed to support the professionals and caregivers who help people stay healthy in the home or care setting of their choice. Its products and solutions are designed to improve patients' quality of life and reduce the impact of chronic disease. Its cloud-based digital health software applications, along with its devices, are designed to provide connected care. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).
ResMed Inc. is a good buy right now due to its current price of $238.97 being below the analyst price targets of $262 and $267, indicating significant upside potential. The stock has shown a strong RSI of 72.818, suggesting bullish momentum, and a solid gross margin of 58.12%, indicating good profitability. However, the recent insider selling by the CEO, who sold nearly 5,000 shares, may raise concerns about future performance, which is a risk to consider.
10 analysts cover RMD: 4 rate it Buy, 2 Hold and 4 Sell. The average price target is 294.00.
Aún no hay publicaciones
Regístrate o inicia sesión para participarEsta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.